GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Buildings And Improvements

Knight Therapeutics (TSX:GUD) Buildings And Improvements : C$0.0 Mil (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Buildings And Improvements?

Knight Therapeutics's quarterly buildings and improvements increased from Sep. 2024 (C$0.0 Mil) to Dec. 2024 (C$18.5 Mil) but then declined from Dec. 2024 (C$18.5 Mil) to Mar. 2025 (C$0.0 Mil).

Knight Therapeutics's annual buildings and improvements declined from Dec. 2022 (C$14.6 Mil) to Dec. 2023 (C$9.8 Mil) but then increased from Dec. 2023 (C$9.8 Mil) to Dec. 2024 (C$18.5 Mil).


Knight Therapeutics Buildings And Improvements Historical Data

The historical data trend for Knight Therapeutics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Buildings And Improvements Chart

Knight Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.30 7.69 14.56 9.84 18.50

Knight Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 18.50 -

Knight Therapeutics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


Knight Therapeutics Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.
Executives
Sime Armoyan 10% Security Holder
Samira Sakhia Director, Senior Officer
Amal Khouri Senior Officer
Jonathan Ross Goodman Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande Director
Long Zone Holdings Inc. 10% Security Holder
Janice Jean Murray Director
Nicolas Sujoy Director
Arvind Utchanah Senior Officer
Michael Joseph Tremblay Director
James Gale Director
Michael Dehn Director, Senior Officer
Andrew Moor Senior Officer
Patrick Mcclymont Senior Officer
Kevin Drew Nabholz Director

Knight Therapeutics Headlines

No Headlines